China Pharma Holdings, Inc.
CPHI · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $756,217 | $1 | $1 | $1 |
| % Growth | 73,722,002.6% | -9.7% | 0.2% | – |
| Cost of Goods Sold | $815,871 | $1 | $1 | $1 |
| Gross Profit | -$59,654 | -$0 | -$0 | -$0 |
| % Margin | -7.9% | -8.5% | -12% | -4.9% |
| R&D Expenses | $40,321 | $0 | $0 | $0 |
| G&A Expenses | $424,827 | $0 | $1 | $1 |
| SG&A Expenses | $502,868 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $78,041 | $0 | $0 | $0 |
| Other Operating Expenses | $25,302 | $0 | -$0 | $0 |
| Operating Expenses | $568,491 | $1 | $1 | $1 |
| Operating Income | -$628,145 | -$1 | -$1 | -$1 |
| % Margin | -83.1% | -63.6% | -66.8% | -105.5% |
| Other Income/Exp. Net | -$23,337 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$651,482 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$651,482 | -$1 | -$1 | -$1 |
| % Margin | -86.2% | -51.5% | -69.1% | -108% |
| EPS | -0.17 | -0.16 | -0.18 | -0.26 |
| % Growth | -6.3% | 11.1% | 30.8% | – |
| EPS Diluted | -0.17 | -0.16 | -0.18 | -0.26 |
| Weighted Avg Shares Out | 4 | 3 | 4 | 5 |
| Weighted Avg Shares Out Dil | 4 | 3 | 4 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $294 | $0 | $0 | $0 |
| Interest Expense | $24,046 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,006,209 | $0 | $0 | $0 |
| EBITDA | $378,773 | -$0 | -$0 | -$1 |
| % Margin | 50.1% | -17.6% | -37.7% | -65.8% |